# Deerfield Management > Deerfield Management is a VC fund backing Health Care and Biotechnology. See 51 investments, check sizes, portfolio and contact details. Updated Aug 2026. - Type: VC Fund - Location: New York, United States - Total investments: 51 - Last investment: Apr 2026 - Lead investor: 45% - Last fund: May 2025 - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/company/deerfield-management - Website: https://deerfield.com Deerfield Management is a VC fund in New York focused on Health Care and Biotechnology. Deerfield Management focuses on advancing healthcare through investment, research, and philanthropic efforts. The firm manages investment strategies that span across public and private markets, targeting companies involved in biotechnology, pharmaceuticals, diagnostics, healthcare services, and medical technology. In addition to capital deployment,Deerfield supports early-stage innovation through strategic partnerships and dedicated facilities that foster scientific research and drug discovery. The organization also operates a philanthropic foundation that funds education, healthcare access, and initiatives aimed at improving health outcomes. ## Contacts 5 contacts available for Deerfield Management. Shizune tracks 5 team members at Deerfield Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/deerfield-management-4e45?utm_source=investor_profile ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Health Care | 20 | 39% | | Biotechnology | 16 | 31% | | Therapeutics | 8 | 16% | | Medical | 7 | 14% | | Biopharma | 6 | 12% | 35 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Post-IPO Equity | 9 | 18% | | Series A | 8 | 16% | | Series B | 6 | 12% | | Series C | 5 | 10% | | Funding Round | 5 | 10% | 8 stages tracked in total. ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 27 | 53% | | Canada | 2 | 4% | | United Kingdom | 2 | 4% | | Israel | 1 | 2% | ## Team | Name | Title | Investments | Profile | | --- | --- | --- | --- | | Cameron Wheeler | Partner | 17 | https://shizune.co/investors/profile/cameron-wheeler | | David Greenwald | Vice President, Business Development | 0 | https://shizune.co/investors/profile/david-greenwald | | Frank Nestle | Partner and Chief Executive Officer | 0 | https://shizune.co/investors/profile/frank-nestle-4bd1 | | Timothy Leahy | Partner | 0 | https://shizune.co/investors/profile/timothy-leahy | | William Slattery | Partner | 5 | https://shizune.co/investors/profile/william-slattery | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Ray Therapeutics | Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases. | $125M | Series B | Apr 21, 2026 | | | Adagene | Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies against novel epitopes. It has its proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody. | $70M | Post-IPO Equity | Apr 02, 2026 | | | Foghorn Therapeutics | Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter whatour DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases. | $50M | Post-IPO Equity | Jan 09, 2026 | | | Excelsior Sciences | Excelsior Sciences develops a chemistry and AI platform for discovering and manufacturing small-molecule compounds. It uses a proprietary “smart bloccs” system, which consists of modular, machine-ready chemical building blocks, to convert small-molecule innovation into an iterative, automation-friendly workflow. Through this platform, Excelsiorenables closed-loop cycles of AI-guided synthesis, testing, and optimisation that link early-stage discovery to scalable manufacturing. The company supports projects across pharmaceuticals, materials science, and other sectors that rely on small molecules. Excelsior also maintains an internal pipeline of therapeutic candidates while working with partners to deploy its chemistry platform broadly. | $70M | Series A | Dec 03, 2025 | | | myLaurel | myLaurel operates in the healthcare industry, providing in-home care, telemedicine, and extended follow-up services. The company's primary goal is to reduce the risk of hospitalizations and re-admissions for patients. myLaurel's unique utilization reduction and readmission prevention programs offer a comprehensive solution for patientpopulations. The company also offers acute care solutions in the home setting. myLaurel's services are backed by private equity and the company operates under private ownership. With Ready Responders, patients now have access to quality whole-person care in their homes, 16 hours a day, 365 days a year, and talented individuals are provided the opportunity to work with a rapidly growing, mission-driven company. They are in-network with most major insurance companies in the markets they serve. Ready Responders is backed by leading venture capital firms, including Google Ventures, Founders Fund, Rise of the Rest, and City Lights Capital. | | | Nov 06, 2025 | | | myLaurel | myLaurel operates in the healthcare industry, providing in-home care, telemedicine, and extended follow-up services. The company's primary goal is to reduce the risk of hospitalizations and re-admissions for patients. myLaurel's unique utilization reduction and readmission prevention programs offer a comprehensive solution for patientpopulations. The company also offers acute care solutions in the home setting. myLaurel's services are backed by private equity and the company operates under private ownership. With Ready Responders, patients now have access to quality whole-person care in their homes, 16 hours a day, 365 days a year, and talented individuals are provided the opportunity to work with a rapidly growing, mission-driven company. They are in-network with most major insurance companies in the markets they serve. Ready Responders is backed by leading venture capital firms, including Google Ventures, Founders Fund, Rise of the Rest, and City Lights Capital. | | | Nov 06, 2025 | | | Reprieve Cardiovascular | Reprieve Cardiovascular is a pioneering medical device company focused on innovative fluid management technologies for congestive heart failure. The company's Reprieve technology is being investigated as an innovative fluid management treatment. Providing clinicians with the ability to precisely control a patient’s fluid volume may both enableimproved cardiac care, as well as, be instrumental in the decongestion of acutely decompensated heart failure patients (ADHF). Reprieve Cardiovascular, Inc. and RenalGuard Solutions, Inc. are subsidiaries of parent company CardioRenal Systems, Inc. | $61M | Series B | Aug 13, 2025 | | | Actio Biosciences | Actio Biosciences involves in the development of precision medicines for homogenous rare patient populations. They develop a pipeline of new medicines with the goal to enhance the probability of clinical success and deliver medicines for all patients. | $66M | Series B | Jun 18, 2025 | | | myLaurel | myLaurel operates in the healthcare industry, providing in-home care, telemedicine, and extended follow-up services. The company's primary goal is to reduce the risk of hospitalizations and re-admissions for patients. myLaurel's unique utilization reduction and readmission prevention programs offer a comprehensive solution for patientpopulations. The company also offers acute care solutions in the home setting. myLaurel's services are backed by private equity and the company operates under private ownership. With Ready Responders, patients now have access to quality whole-person care in their homes, 16 hours a day, 365 days a year, and talented individuals are provided the opportunity to work with a rapidly growing, mission-driven company. They are in-network with most major insurance companies in the markets they serve. Ready Responders is backed by leading venture capital firms, including Google Ventures, Founders Fund, Rise of the Rest, and City Lights Capital. | $12M | | Jun 03, 2025 | | | myLaurel | myLaurel operates in the healthcare industry, providing in-home care, telemedicine, and extended follow-up services. The company's primary goal is to reduce the risk of hospitalizations and re-admissions for patients. myLaurel's unique utilization reduction and readmission prevention programs offer a comprehensive solution for patientpopulations. The company also offers acute care solutions in the home setting. myLaurel's services are backed by private equity and the company operates under private ownership. With Ready Responders, patients now have access to quality whole-person care in their homes, 16 hours a day, 365 days a year, and talented individuals are provided the opportunity to work with a rapidly growing, mission-driven company. They are in-network with most major insurance companies in the markets they serve. Ready Responders is backed by leading venture capital firms, including Google Ventures, Founders Fund, Rise of the Rest, and City Lights Capital. | $12M | | Jun 03, 2025 | | 10 of 51 investments shown. ## Co-investors - [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 7 deals together - [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 7 deals together - [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 6 deals together - [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 6 deals together - [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 5 deals together - [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 5 deals together ## Similar investors ### Similar stage - [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund - [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund - [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund ## FAQ ### What does Deerfield Management invest in? Deerfield Management invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Post-IPO Equity and Series A stage. Most of the 51 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### How do I contact Deerfield Management? Public channels for Deerfield Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox. ### Who are the partners at Deerfield Management? The team at Deerfield Management includes Cameron Wheeler (Partner), David Greenwald (Vice President, Business Development) and Frank Nestle (Partner and Chief Executive Officer). The Team section lists each member with their title, investment count and links. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co